PHAXIAM Therapeutics (PHAXIAM Therapeutics) Days Sales Outstanding : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PHAXIAM Therapeutics Days Sales Outstanding?

PHAXIAM Therapeutics's average Accounts Receivable for the three months ended in Sep. 2023 was $0.27 Mil. PHAXIAM Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for PHAXIAM Therapeutics's Days Sales Outstanding or its related term are showing as below:

PHXM's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

PHAXIAM Therapeutics's Days Sales Outstanding stayed the same from Jun. 2022 (0.00) to Sep. 2023 (0.00).

PHAXIAM Therapeutics Days Sales Outstanding Historical Data

The historical data trend for PHAXIAM Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Days Sales Outstanding Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PHAXIAM Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, PHAXIAM Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Days Sales Outstanding falls into.

PHAXIAM Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

PHAXIAM Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0.014	+	0.081)	/	2 )	/	0	*	365
=	0.0475					/	0	*	365
=	N/A

PHAXIAM Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding (Q: Sep. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )	*	Days in Period
=	( (0.265	+	0)	/	1 )	/	0	*	365 / 4
=	0.265					/	0	*	365 / 4
=	N/A

PHAXIAM Therapeutics (NAS:PHXM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

PHAXIAM Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (PHAXIAM Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (NAS:PHXM) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PHXM:France 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.